Last reviewed · How we verify

NCT05818033

Safety and Effectiveness of CARE1.02 Spectacle Lens in Myopia Control

Completed NA Last updated 12 March 2026
What this trial tests

NA trial testing CARE1.02 in Myopia in 796 participants. Completed in 12 June 2025.

Timeline
25 April 2023
Primary endpoint
12 June 2025
12 June 2025

Quick facts

Lead sponsorZhongshan Ophthalmic Center, Sun Yat-sen University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment796
Start date25 April 2023
Primary completion12 June 2025
Estimated completion12 June 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University

Who can join

Adults 12 to 17, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

China is a major country in myopia, with the highest number of teenagers suffering from myopia. Controlling the progression of myopia and the related complications caused by axial elongation have clinical significance and social value. Currently. There is a lack of researches on the impact of specially designed myopia control spectacle lens in adolescents aged 12 and above. Therefore, The researchers plan to conduct a randomized controlled trial among myopia adolescents aged 12-17 in middle and high schools in Guangzhou, to test and verify the safety and effectiveness of CARE1.02 on myopia control compared with single-vision spectacle lens.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Myopia

Currently open trials in the same condition.

Other Zhongshan Ophthalmic Center, Sun Yat-sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05818033.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing